Abstract
Over the last few years, BRAF has emerged as a validated target in melanoma. This review summarises recent advances in the development of BRAF inhibitors, focussing on agents that have been assessed clinically.
Copyright © 2011 Elsevier Ltd. All rights reserved.
MeSH terms
-
Clinical Trials as Topic*
-
Humans
-
Melanoma / drug therapy*
-
Melanoma / metabolism
-
Molecular Weight
-
Protein Kinase Inhibitors / chemistry
-
Protein Kinase Inhibitors / pharmacology*
-
Proto-Oncogene Proteins B-raf / antagonists & inhibitors*
-
Proto-Oncogene Proteins B-raf / genetics
-
Proto-Oncogene Proteins B-raf / metabolism
-
Structure-Activity Relationship
Substances
-
Protein Kinase Inhibitors
-
Proto-Oncogene Proteins B-raf